Jump to content

Drug for Ovarian Cancer effective for Prostate Cancer

Paul Edwards

Recommended Posts

Olabarib is a drug which the United States Food and Drug Administration (FDA) has approved for the treatment of ovarian cancer patients with mutations of the BRCA1and BRCA2 genes, which play key roles in DNA damage repair.   Mutations in these genes have been linked with the development and progression of many tumour types, including prostate cancer.


A clinical study has shown that Olaparib is highly effective at treating men with DNA repair defects in their tumours.  About 30% of men with prostate cancer have DNA repair defects in their tumours - either they have inherited mutations in the BRCA1 and BRCA2 genes or, as their cancer has progressed, their tumours have developed defects in DNA repair.


Further clinical trials will be necessary before Olaparib will be generally available for prostate cancer patients.  Because the FDA has already approved Olaparib for the treatment of ovarian cancer, it is likely to speed up the approval process to use Olaparib for prostate cancer.


Click on this link for further information about this research.


[Some of our members are aware that they have the BRCA1 and BRCA2 genes - this is very exciting news for them.  One of the men that I met at the PCRI conference in Los Angeles last month was being treated with Olaparib.]

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...